Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized ...

The World Business Council for Sustainable Development (WBCSD), in collaboration with leading pharmaceutical companies and ...

The Trump Administration has implemented or proposed a broad range of tariffs, including on pharmaceuticals. Careful ...

Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 10.02%, which has investors questioning if this is right time to sell.

The integration of AI and cloud technologies is transforming pharmaceutical manufacturing regulations, focusing on safety, efficiency, and global harmonization.

Selvaraja Elumalai - distinguished quality control professionals with an experience of more than twenty years in the ...

A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...